AIRLINK 78.39 Increased By ▲ 5.39 (7.38%)
BOP 5.34 Decreased By ▼ -0.01 (-0.19%)
CNERGY 4.33 Increased By ▲ 0.02 (0.46%)
DFML 30.87 Increased By ▲ 2.32 (8.13%)
DGKC 78.51 Increased By ▲ 4.22 (5.68%)
FCCL 20.58 Increased By ▲ 0.23 (1.13%)
FFBL 32.30 Increased By ▲ 1.40 (4.53%)
FFL 10.22 Increased By ▲ 0.16 (1.59%)
GGL 10.29 Decreased By ▼ -0.10 (-0.96%)
HBL 118.50 Increased By ▲ 2.53 (2.18%)
HUBC 135.10 Increased By ▲ 2.90 (2.19%)
HUMNL 6.87 Increased By ▲ 0.19 (2.84%)
KEL 4.17 Increased By ▲ 0.14 (3.47%)
KOSM 4.73 Increased By ▲ 0.13 (2.83%)
MLCF 38.67 Increased By ▲ 0.13 (0.34%)
OGDC 134.85 Increased By ▲ 1.00 (0.75%)
PAEL 23.40 Decreased By ▼ -0.43 (-1.8%)
PIAA 26.64 Decreased By ▼ -0.49 (-1.81%)
PIBTL 7.02 Increased By ▲ 0.26 (3.85%)
PPL 113.45 Increased By ▲ 0.65 (0.58%)
PRL 27.73 Decreased By ▼ -0.43 (-1.53%)
PTC 14.60 Decreased By ▼ -0.29 (-1.95%)
SEARL 56.50 Increased By ▲ 0.08 (0.14%)
SNGP 66.30 Increased By ▲ 0.50 (0.76%)
SSGC 10.94 Decreased By ▼ -0.07 (-0.64%)
TELE 9.15 Increased By ▲ 0.13 (1.44%)
TPLP 11.67 Decreased By ▼ -0.23 (-1.93%)
TRG 71.43 Increased By ▲ 2.33 (3.37%)
UNITY 24.51 Increased By ▲ 0.80 (3.37%)
WTL 1.33 No Change ▼ 0.00 (0%)
BR100 7,494 Increased By 60.2 (0.81%)
BR30 24,599 Increased By 379.2 (1.57%)
KSE100 72,052 Increased By 692.5 (0.97%)
KSE30 23,808 Increased By 241 (1.02%)

Russia aims to produce 'millions' of virus doses by 2021

  • Gamaleya's vaccine is a so-called viral vector vaccine, meaning it employs another virus to carry the DNA encoding of the needed immune response into cells.
Published August 3, 2020

MOSCOW: Russia said Monday it aims to launch mass production of a coronavirus vaccine next month and turn out "several million" doses per month by next year.

The country is pushing ahead with several vaccine prototypes and one prepared at the Gamaleya institute in Moscow has reached advanced stages of development.

"We are very much counting on starting mass production in September," industry minister Denis Manturov said in an interview published by TASS news agency.

"We will be able to ensure production volumes of several hundred thousand a month, with an eventual increase to several million by the start of next year," he said, adding that one developer is preparing production technology at three locations in central Russia.

Health Minister Mikhail Murashko on Saturday said the Gamaleya vaccine had "completed clinical trials" and that documents were being prepared to register it with the state.

Another vaccine, developed by Siberia-based Vektor lab, is currently undergoing clinical trials and two more will begin human testing within the next two months, Murashko said.

Gamaleya's vaccine is a so-called viral vector vaccine, meaning it employs another virus to carry the DNA encoding of the needed immune response into cells.

Gamaleya's vaccine employs the adenovirus, a similar technology to the coronavirus vaccine prototype developed by China's CanSino, currently in the advanced stage of clinical trials.

The Gamaleya institute came under fire after researchers and directors injected themselves with the prototype months ago, with specialists criticising the move as an unorthodox and rushed way of starting human trials.

Scientists have told AFP that Russia will struggle to adapt the vaccine to mass production because the country lacks raw materials, adequate facilities and experience, particularly with advanced technology like viral vector.

Some Russian officials have boasted that the country will be the first to come up with the vaccine, even comparing it to the space race to produce the first satellite in the Soviet era.

Moscow has dismissed allegations from the UK, the United States and Canada that a hacking group linked to Russian intelligence services tried to steal information about a coronavirus vaccine from labs in the West.

Russia's coronavirus caseload is currently fourth in the world after the United States, Brazil and India.

Comments

Comments are closed.